Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances

(2014) Florian Cabillic et al.   Journal of Thoracic Oncology

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma

(2013) J. Ying et al.   ANNALS OF ONCOLOGY

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

(2013) Ka-Fai To et al.   Journal of Thoracic Oncology

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology

(2013) Neal I. Lindeman et al.   Journal of Thoracic Oncology

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas

(2013) Lynette M. Sholl et al.   Journal of Thoracic Oncology

Treatment and detection of ALK-rearranged NSCLC

(2013) Solange Peters et al.   LUNG CANCER

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization

(2013) Christina I Selinger et al.   MODERN PATHOLOGY

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development

(2012) Giorgio Scagliotti et al.   EUROPEAN JOURNAL OF CANCER

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

(2012) D Ross Camidge et al.   LANCET ONCOLOGY

Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

(2012) Sai-Hong Ignatius Ou et al.   ONCOLOGIST

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

(2012) Erik Thunnissen et al.   VIRCHOWS ARCHIV

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

(2011) L. V. Sequist et al.   ANNALS OF ONCOLOGY

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer

(2011) June Koo Lee et al.   CANCER

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement

(2011) Hye Ryun Kim et al.   CANCER

Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization

(2011) Jin Ho Paik et al.   Journal of Thoracic Oncology

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

(2011) D. Ross Camidge et al.   Journal of Thoracic Oncology

Worse Disease-Free Survival in Never-Smokers with ALK+ Lung Adenocarcinoma

(2011) Ping Yang et al.   Journal of Thoracic Oncology

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR

(2011) Shang-Gin Wu et al.   Journal of Thoracic Oncology

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study

(2011) Anne McLeer-Florin et al.   Journal of Thoracic Oncology

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer

(2011) Jin Ho Paik et al.   LUNG CANCER

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

(2010) D. R. Camidge et al.   CLINICAL CANCER RESEARCH

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer

(2010) Benjamin Solomon et al.   Journal of Thoracic Oncology

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

(2010) Josef Rüschoff et al.   VIRCHOWS ARCHIV

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population

(2009) S. J. Rodig et al.   CLINICAL CANCER RESEARCH

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers

(2008) Kentaro Inamura et al.   Journal of Thoracic Oncology